Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].
In: Expert review of pharmacoeconomics & outcomes research, Jg. 22 (2022-06-01), Heft 4, S. 581-598
academicJournal
Zugriff:
Background: Conventional cost-effectiveness analysis [CEA] using cost per QALY thresholds may counteract other incentives introduced to foster development of treatments for rare and ultra-rare diseases. Therefore, alternative economic evaluation methods were explored, namely Discrete Choice Experiment Willingness to Pay (DCE-WTP) and Relative Social Willingness to Pay (RS-WTP), to value interventions for an ultra-rare childhood disease, Neuronal Ceroid Lipofuscinosis type 2 (CLN2).
Research Design and Methods: Treatment for CLN2 was valued from a citizen's ('social') perspective using DCE-WTP and RS-WTP in a survey of 4,009 United Kingdom [UK] adults. Three attributes (initial quality of life, treatment effect, and life expectancy) were used in both analyses. For DCE-WTP, a cost attribute (marginal income tax increase) was also included. Optimal econometric models were identified.
Results: DCE-WTP indicated that UK adults are willing to pay incremental increases through taxation for improvements in CLN2 attributes. RS-WTP identified a willingness to allocate >40% of a pre-assigned healthcare budget to prevent child mortality and approximately 15% for improved health status.
Conclusions: Both techniques illustrate substantive social WTP for CLN2 interventions, despite the small number of children benefitting. This highlights a gap between UK citizens' willingness to spend on rare disease interventions and current funding policies.
Titel: |
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].
|
---|---|
Autor/in / Beteiligte Person: | Moro, D ; Schlander, M ; Telser, H ; Sola-Morales, O ; Clark, MD ; Olaye, A ; Camp, C ; Jain, M ; Butt, T ; Bakshi, S |
Zeitschrift: | Expert review of pharmacoeconomics & outcomes research, Jg. 22 (2022-06-01), Heft 4, S. 581-598 |
Veröffentlichung: | 2015- : Abingdon, Oxford : Taylor & Francis ; <i>Original Publication</i>: London : Future Drugs Ltd, [2001-, 2022 |
Medientyp: | academicJournal |
ISSN: | 1744-8379 (electronic) |
DOI: | 10.1080/14737167.2022.2014324 |
Schlagwort: |
|
Sonstiges: |
|